Compare Hyatt Hotels Corporation (H) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Organon & Co. Common Stock — how do they compare? Hyatt Hotels Corporation trades at $160.32 (market cap $15.35B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Hyatt Hotels Corporation is far larger — about 4.2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 149 Days and Organon & Co. Common Stock for 0 Days on average.
| H | OGN | |
|---|---|---|
Market Cap | $15.35B | $3.62B |
Volume | 614,954 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $13.81 |
52-Week Low | $135.42 | $5.70 |
Typical Hold Time | 149 Days | 0 Days |
Enterprise Value | $19.26B | $11.04B |
Dividend Yield | 0.37% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels Corporation (H) trades at $160.32, down 0.53% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows a high P/E ratio of 201.14 but benefits from a strategic collaboration with Delta Air Lines and portfolio expansion. Cash flow trends indicate variability, with a net cash outflow of $227 million in 2025, while revenue grew to $7.10 billion.
The outlook is mixed: analyst consensus is a Moderate Buy with a $197.92 price target, implying 23% upside, but risks include high valuation, debt levels, and net income volatility. Growth drivers include brand expansion and loyalty partnerships, yet investors should monitor execution on profitability and macroeconomic impacts on travel demand.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
